The SGLT2 Inhibitor Canagliflozin Reduces Atherosclerosis by Enhancing Macrophage Autophagy

[1] Moore KJ(2011)Macrophages in the pathogenesis of atherosclerosis Cell 145 341-355

[2] Tabas I(1999)Atherosclerosis–an inflammatory disease N Engl J Med 340 115-126

[3] Ross R(2012)DNA damage and repair in atherosclerosis: current insights and future perspectives Int J Mol Sci 13 16929-16944

[4] Cervelli T(2014)Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia Am J Physiol Renal Physiol 306 F188-F193

[5] Borghini A(2021)SGLT2 inhibitors may offer benefit beyond diabetes Nat Rev Nephrol 17 83-84

[6] Galli A(2021)SGLT2 inhibitors in people with and without T2DM Nat Rev Endocrinol 17 75-76

[7] Andreassi MG(2020)SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control Nat Rev Cardiol 17 761-772

[8] Rieg T(2017)SGLT2 inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice EBioMedicine 20 137-149

[9] Masuda T(2018)Emerging roles of SGLT2 inhibitors in obesity and insulin resistance: focus on fat browning and macrophage polarization Adipocyte 7 121-128

[10] Gerasimova M(2021)Autophagy in metabolic disease and ageing Nat Rev Endocrinol 17 647-661

[1] Moore KJ(2011)Macrophages in the pathogenesis of atherosclerosis Cell 145 341-355

[2] Tabas I(1999)Atherosclerosis–an inflammatory disease N Engl J Med 340 115-126

[3] Ross R(2012)DNA damage and repair in atherosclerosis: current insights and future perspectives Int J Mol Sci 13 16929-16944

[4] Cervelli T(2014)Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia Am J Physiol Renal Physiol 306 F188-F193

[5] Borghini A(2021)SGLT2 inhibitors may offer benefit beyond diabetes Nat Rev Nephrol 17 83-84

[6] Galli A(2021)SGLT2 inhibitors in people with and without T2DM Nat Rev Endocrinol 17 75-76

[7] Andreassi MG(2020)SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control Nat Rev Cardiol 17 761-772

[8] Rieg T(2017)SGLT2 inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice EBioMedicine 20 137-149

[9] Masuda T(2018)Emerging roles of SGLT2 inhibitors in obesity and insulin resistance: focus on fat browning and macrophage polarization Adipocyte 7 121-128

[10] Gerasimova M(2021)Autophagy in metabolic disease and ageing Nat Rev Endocrinol 17 647-661